Please login to the form below

Not currently logged in
Email:
Password:

Seretide

This page shows the latest Seretide news and features for those working in and with pharma, biotech and healthcare.

Advair generics and acquisitions to hit GSK in 2019

Advair generics and acquisitions to hit GSK in 2019

The flat performance in pharma has been in part due to GSK discounting Advair (Seretide in the rest of the world), ahead of the arrival of the generic competitors.

Latest news

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate)

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    Anoro is one of the drugs GSK is hoping will help replace its COPD blockbuster Seretide/Advair (salmeterol/fluticasone propionate), which has lost patent protection and seen revenues slide in recent

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    of patent protection for COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol), even though competition in the US has been delayed by stringent FDA requirements for low-cost generics that have delayed ... Total respiratory franchise sales

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    GSK has a lot riding on Trelegy as it tries to restore growth in its respiratory business, which has been hit by patent expiries for two-drug COPD blockbuster Seretide/Advair

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    GSK has a lot riding on Trelegy as it tries to grow its respiratory business, which has been hit by patent expiries for COPD blockbuster Seretide/Advair (salmeterol and fluticasone propionate) -

More from news
Approximately 9 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    Only Seretide/Advair ($8.4bn), Abilify ($8bn) and Crestor ($6.9bn) prevented a biologic clean sweep of the bestsellers. .

  • What can pharma learn from Olympic sports coverage? What can pharma learn from Olympic sports coverage?

    Over the years, the corporation has built a wealth of knowledge in the field, and built and maintained a leading portfolio of respiratory products from Ventolin in 1969 through to Seretide,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics